Fazamorexant
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Fazamorexant
- Molecular weight
- 432.5
- Structure (SMILES)
- Cc1ccc(-c2ncccn2)c(C(=O)N2[C@H]3CC[C@@H](COc4ccc(F)cn4)[C@@H]2CC3)c1
- fazamorexant
- Fazamorexant
- fazamorexant [INN]
- fazamorexant inn
- yzj 1139
- YZJ-1139
- YZJ-1139 10mg
- YZJ-1139 20mg
- YZJ-1139 40mg
- YZJ-1139 60mg
- YZJ-1139 tablets
- CAS registry numbers
- 1808918-69-5
- ChEMBL ID
- CHEMBL5314459
- InChIKey
- PMJPLAGTPPVSRL-JLMWRMLUSA-N
- PubChem compound IDs
- 156889652
- FDA ingredient codes (UNII)
- MDH4D7M594
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- fazamorexant
- Type
- Synthetic organic
- Action
- Antagonist
- Action type
- Antagonist
- Target
- OX1 receptor
- Gene symbol
- HCRTR1
- Protein identifier
- O43613
- Median affinity
- 7.7
- Affinity units
- pIC50
- Action
- Antagonist
- Action type
- Antagonist
- Target
- OX2 receptor
- Gene symbol
- HCRTR2
- Protein identifier
- O43614
- Median affinity
- 7.44
- Affinity units
- pIC50
Investigated indications
- Condition
- Sleep Initiation and Maintenance Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004698
- Subject identifier
- D007319
- Condition identifier
- EFO_0004698
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0013600
- Highest recorded phase
- 3
Trial references
- NCT05525637
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 0
- Polar surface area
- 68.21
- Calculated partition coefficient (ALogP)
- 4.45
- Calculated partition coefficient (XLogP)
- 4.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 32
- Molecular formula
- C25H25FN4O2
- Monoisotopic mass
- 432.19615422
- Natural product
- No
Related records
Trials (9)
- A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets
- A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants
- Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment
- Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment
- PK/PD Study of YZJ-1139
- Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder
- Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder
- Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder
In development for (1)
- Insomnia Phase 3